Lancashire and South Cumbria
Formulary
Formulary
1 Gastro-intestinal system
01-09-01 Drugs affecting biliary composition and flow
| Elafibranor |
|
Formulary
|
All patients must be referred to the ELHT PBC Network Lead to confirm eligibility. Prescribing (initiation and continuation) is restricted to ELHT only. |
 NICE TA1016: Elafibranor for previously treated primary biliary cholangitis |
|
| Obeticholic acid Ocaliva® |
|
Formulary
|
Tablets 5mg, 10mg Specialist use only |
|
MHRA: Obeticholic acid (Ocaliva▼): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
|
|
Links
Biosimilars policy statement- Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Primary Care Constipation Guidelines
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Obeticholic acid (Ocaliva▼): risk of serious liver injury in patients with pre-existing moderate or severe hepatic impairment; reminder to adjust dosing according to liver function monitoring
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA1016: Elafibranor for previously treated primary biliary cholangitis
- NICE TA443: Obeticholic acid for treating primary biliary cholangitis